[en] Aripiprazole, brexpiprazole and cariprazine are dopamine D2 receptor ligands considered as effective and tolerable antipsychotics. Brain imaging studies showed that schizophrenia is characterized by elevated dopamine receptor density, which is exacerbated by antipsychotic treatments. Despite the complexity of translating in vitro studies to human neurobiology, overexpression experiments in transfected cells provide a proof-of-concept model of the influence of receptor density on antipsychotic treatments. Since receptor density was demonstrated to influence the signaling profile of dopaminergic ligands, we hypothesized that high dopamine D2 receptor expression levels could influence the recruitment of Gi1 and β-arrestin2 in response to partial agonists used as antipsychotics. A nanoluciferase complementation assay was used to monitor β-arrestin2 and Gi1 recruitment at the dopamine D2L receptor in response to aripiprazole, brexpiprazole and cariprazine. This was performed in transfected cells carrying a doxycycline-inducible system allowing to manipulate the expression of the dopamine D2L receptors. Increasing D2L receptor density reoriented aripiprazole's preferential recruitment from Gi1 to β-arrestin2. With respect to brexpiprazole, which showed inverse agonism for β-arrestin2 recruitment at the lower receptor density tested, inverse agonism for Gi1 recruitment was observed when tested at a high receptor expression level. At variance, cariprazine evoked a potent partial agonism for β-arrestin2 recruitment only, in all the tested conditions. D2L receptor density appears to shape the recruitment bias of aripiprazole and brexpiprazole, but not cariprazine. This suggests that changes in receptor expression level could qualitatively influence the functional response of partial agonists used in psychiatry.
El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev. 2006;189:102-108. doi:10.1002/14651858.cd004578.pub3
Ribeiro ELA, de Mendonça Lima T, Vieira MEB, Storpirtis S, Aguiar PM. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018;74(10):1215-1233. doi:10.1007/s00228-018-2498-1
Bosier B, Hermans E. Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance. Trends Pharmacol Sci. 2007;28(8):438-446. doi:10.1016/j.tips.2007.06.001
Hermans E. Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol Ther. 2003;99(1):25-44. doi:10.1016/S0163-7258(03)00051-2
Kenakin T. Biased receptor signaling in drug discovery. Pharmacol Rev. 2019;71(2):267-315. doi:10.1124/pr.118.016790
Urban JD, Clarke WP, Von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 2007;320(1):1-13. doi:10.1124/jpet.106.104463
Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell. 2005;122(2):261-273. doi:10.1016/j.cell.2005.05.012
Beaulieu JM, Gainetdinov RR, Caron MG. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci. 2007;28(4):166-172. doi:10.1016/j.tips.2007.02.006
Allen JA, Yost JM, Setola V, et al. Discovery of β-arrestin-biased dopamine D 2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A. 2011;108(45):18488-18493. doi:10.1073/pnas.1104807108
Masri B, Salahpour A, Didriksen M, et al. Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A. 2008;105(36):13656-13661. doi:10.1073/pnas.0803522105
Brust TF, Hayes MP, Roman DL, Burris KD, Watts VJ. Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways. J Pharmacol Exp Ther. 2015;352(3):480-493. doi:10.1124/jpet.114.220293
Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381-389. doi:10.1124/jpet.102.033175
Jordan S, Johnson JL, Regardie K, et al. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):348-356. doi:10.1016/j.pnpbp.2006.09.007
Koener B, Focant MC, Bosier B, Maloteaux JM, Hermans E. Increasing the density of the D 2L receptor and manipulating the receptor environment are required to evidence the partial agonist properties of aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(1):60-70. doi:10.1016/j.pnpbp.2011.08.007
Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400-1411. doi:10.1038/sj.npp.1300203
Tadori Y, Miwa T, Tottori K, et al. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol. 2005;515(1-3):10-19. doi:10.1016/j.ejphar.2005.02.051
Nordström AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33(4):227-235. doi:10.1016/0006-3223(93)90288-O
Stahl SM, Stahl SM, Muntner N. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press; 2013. https://books.google.be/books?id=BBtMzTV8OMgC
Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol. 2017;7(1):29-41. doi:10.1177/2045125316672136
Laschet C, Dupuis N, Hanson J. A dynamic and screening-compatible nanoluciferase-based complementation assay enables profiling of individual GPCR–G protein interactions. J Biol Chem. 2019;294(11):4079-4090. doi:10.1074/jbc.RA118.006231
Ferraiolo M, Atik H, Ponthot R, Koener B, Hanson J, Hermans E. Dopamine D2L receptor density influences the recruitment of β-arrestin2 and Gi1 induced by antiparkinsonian drugs. Neuropharmacology. 2022;207:108942. doi:10.1016/J.NEUROPHARM.2022.108942
Hall MP, Unch J, Binkowski BF, et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem Biol. 2012;7(11):1848-1857. doi:10.1021/cb3002478
Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003;166(4):391-399. doi:10.1007/s00213-002-1344-3
Koener B, Emmanuel H, Maloteaux JM, Jean-Jean A, Constant EL. Paradoxical motor syndrome following a switch from atypical neuroleptics to aripiprazole [5]. Am J Psychiatry. 2007;164(9):1437-1438. doi:10.1176/appi.ajp.2007.07020363
Koener B, Goursaud S, van de Stadt M, et al. Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization. Naunyn Schmiedebergs Arch Pharmacol. 2011;383(1):65-77. doi:10.1007/s00210-010-0577-7
Gazi L, Bobirnac I, Danzeisen M, et al. Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells. Br J Pharmacol. 1999;128(3):613-620. doi:10.1038/sj.bjp.0702849
Laschet C, Hanson J. Nanoluciferase-based complementation assay to detect GPCR-G protein interaction. Methods Mol Biol. 2021;2268:149-157. doi:10.1007/978-1-0716-1221-7_10
Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, Novick S. A simple method for quantifying functional selectivity and agonist bias. ACS Chem Nerosci. 2012;3(3):193-203. doi:10.1021/cn200111m
Nagi K, Pineyro G. Practical guide for calculating and representing biased signaling by GPCR ligands: a stepwise approach. Methods. 2016;92:78-86. doi:10.1016/j.ymeth.2015.09.010
Kolb P, Gloriam D, Breinholt S, Bouvier M, Ehlert F, Hill SJ, Martemyanov K, Neubig R. International Union of Basic and Clinical Pharmacology. Recommendations for GPCR ligand bias author list; 2021:1-27.
Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol. 1997;321(1):105-111. doi:10.1016/S0014-2999(96)00920-X
Kikuchi T, Tottori K, Uwahodo Y, et al. 7-{4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy}-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther. 1995;274(1):329-336.
Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D 3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328-340. doi:10.1124/jpet.109.160432
Gao Y, Peterson S, Masri B, et al. Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions. Pharmacol Res Perspect. 2015;3(1):1-10. doi:10.1002/prp2.73
Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin–dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589-604. doi:10.1124/jpet.114.213793
Akam E, Strange PG. Inverse agonist properties of atypical antipsychotic drugs. Biochem Pharmacol. 2004;67(11):2039-2045. doi:10.1016/j.bcp.2004.02.017
Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol. 2004;65(1):2-11. doi:10.1124/mol.65.1.2
Ferraiolo M, Atik H, Ponthot R, et al. Receptor density influences ligand-induced dopamine D2L receptor homodimerization. Eur J Pharmacol. 2021;911(July):174557. doi:10.1016/j.ejphar.2021.174557
Han Y, Moreira IS, Urizar E, Weinstein H, Javitch JA. Allosteric communication between protomers of dopamine class a GPCR dimers modulates activation. Nat Chem Biol. 2009;5(9):688-695. doi:10.1038/nchembio.199
Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63(1):182-217. doi:10.1124/pr.110.002642
Martinez VJ, Asico LD, Jose PA, Tiu AC. Lipid rafts and dopamine receptor signaling. Int J Mol Sci. 2020;21(23):1-18. doi:10.3390/IJMS21238909
Sibley D, Hazelwood L, Roof R, Free RB, Han Y, Javitch J. P02-314—membrane lipid rafts are required for D2 dopamine receptor signaling. Eur Psychiatry. 2011;26(S2):910. doi:10.1016/S0924-9338(11)72615-3
